Business Description
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Share Class Description:
AGIO: Ordinary SharesCompare
Compare
Traded in other countries / regions
AGIO.USAAGIO.Mexico0HB0.UK8AP.Germany IPO Date
2013-07-24Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.82 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 11.23 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.5 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | -8.6 | |||||
| 3-Year Book Growth Rate | 36 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 92.71 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.99 | |||||
| 9-Day RSI | 64.26 | |||||
| 14-Day RSI | 58.66 | |||||
| 6-1 Month Momentum % | 44.84 | |||||
| 12-1 Month Momentum % | 128.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.09 | |||||
| Quick Ratio | 9.71 | |||||
| Cash Ratio | 9.1 | |||||
| Days Inventory | 2163.74 | |||||
| Days Sales Outstanding | 31.37 | |||||
| Days Payable | 1220.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 6.9 | |||||
| Shareholder Yield % | 0.54 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.33 | |||||
| Operating Margin % | -1293.88 | |||||
| Net Margin % | -1165.69 | |||||
| FCF Margin % | -1038.1 | |||||
| ROE % | -44.87 | |||||
| ROA % | -39.22 | |||||
| ROIC % | -166.58 | |||||
| 3-Year ROIIC % | 39.42 | |||||
| ROC (Joel Greenblatt) % | -475.24 | |||||
| ROCE % | -46.49 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 82.71 | |||||
| PB Ratio | 3.97 | |||||
| Price-to-Tangible-Book | 3.97 | |||||
| EV-to-EBIT | -5.09 | |||||
| EV-to-Forward-EBIT | -0.81 | |||||
| EV-to-EBITDA | -5.16 | |||||
| EV-to-Revenue | 65.8 | |||||
| EV-to-Forward-Revenue | 18.64 | |||||
| EV-to-FCF | -6.34 | |||||
| Price-to-Net-Current-Asset-Value | 5.04 | |||||
| Price-to-Net-Cash | 5.73 | |||||
| Earnings Yield (Greenblatt) % | -19.65 | |||||
| FCF Yield % | -12.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 31.306 | ||
| EPS (TTM) ($) | -6.5 | ||
| Beta | 0.5 | ||
| Volatility % | 51.79 | ||
| 14-Day RSI | 58.66 | ||
| 14-Day ATR ($) | 1.721791 | ||
| 20-Day SMA ($) | 43.04375 | ||
| 12-1 Month Momentum % | 128.39 | ||
| 52-Week Range ($) | 20.04 - 53.285 | ||
| Shares Outstanding (Mil) | 56.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agios Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(AGIO)'s stock price today?
The current price of AGIO is $46.08. The 52 week high of AGIO is $53.29 and 52 week low is $20.04.
When is next earnings date of Agios Pharmaceuticals Inc(AGIO)?
The next earnings date of Agios Pharmaceuticals Inc(AGIO) is 2024-10-31.
Does Agios Pharmaceuticals Inc(AGIO) pay dividends? If so, how much?
Agios Pharmaceuticals Inc(AGIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers